Sanofi: Q2'26 preview: BARC slightly ahead for Q2, see room for slight FY26 LC guidance upgrade, new CEO strategy in focus

Research evidence excerpt

Sanofi: Q2'26 preview: BARC slightly ahead for Q2, see room for slight FY26 LC guidance upgrade, new CEO strategy in focus

r soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers,

directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue,

loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this

publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication (including third-party data) has been obtained from sources

that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Third-party data, including

third-party forecasts and predictions, is provided for information purposes only, has not been adopted or endorsed by Barclays, and does not

represent the views or opinions of Barclays. Presentations by Third-Party Speakers: Any views or opinions expressed by third-party speakers during a

Barclays-hosted event are solely those of the speaker and do not represent the views or opinions of Barclays. Barclays is not responsible for, and

makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations by any third-

party speakers, and such presentations have not been adopted or endorsed by Barclays and do not represent the views or opinions of Barclays.